The toxicity of BMS-182248, an immunoglobulin (cBR96)-cytotoxic drug (doxorubicin) conjugate, was investigated in Sprague-Dawley rats at single intravenous doses of 508, 1,200, and 2,550 mg/m 2 (conjugated doxorubicin doses of 14.7, 34.8, and 74 mg/m 2 , respectively) and compared to that obtained from administration of free doxorubicin at single doses of 33.6 and 72 mg/m 2 (approximately equivalent to that contained in the 1,200-and 2,550-mg/m 2 doses of BMS-182248, respectively). Necropsies were conducted on day 8, upon death/moribund sacrifice, or after an approximate 3-mo observation period following completion of treatment.
INTRODUCTION
B1VIS-182248 is a chimeric antibody (cBR96)-cytotoxic drug (doxorubicin) conjugate being developed for the treatment of tumors that express Lewisy-related antigens. The antibody BR96, containing human heavy (IgG,)-/and light (K~--~hain constant regions, has been shown to bind to tumors of the breast, lung, and colon (3.4) . ? 248 has been reported to induce complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing subcutaneously in athymic mice and rats (13) .
One potential advantage of a doxorubicin immunoconjugate is an overall reduction of toxicity compared to free (unbound) doxorubicin and particularly of cardiotoxicity. because the clinical use of doxorubicin is generally limited by deleterious effects on the myocardium that are delayed in onset and can be lethal ( 1 1 ) . Cardiotoxicitv in the rat. as a result of administration of free doxorubicin. has been well documented in the literature using dosing Abbreviations: F = female; M = male. 11 Doses in parentheses are the equivalent amount of conjugated doxorubicin. &dquo; Five rats in Groups 1-4 necropsied on day 8; remaining rats necropsied at 3 mo. schedules varying from once a week for 12 wk to a single dose ( 10, 14) .
The purpose of this study was to investigate the toxicity of BMS-182248 following single intravenous doses and to compare its toxicologic profile to similar doses of free doxorubicin that have been demonstrated to induce delayed cardiotoxicity in rats.
In this study, there was significant reduction in overall toxicity, especially delayed cardiotoxicity, in rats given single doses of doxorubicin conjugated to BR96 monoclonal antibody.
METHODS
Test Materials. Supplies of BMS-182248 were obtained from Bristol-Myers Squibb Company, De- partment of Chemical Process Research (New Brunswick, NJ). Doxorubicin hydrochloride was obtained from Adria Laboratories (Dublin, OH). Supplies of Dulbecco's phosphate-buffered saline (DPBS), which were used to prepare dilute solutions of BMS-182248 and to dose control rats, and supplies of 0.9% sodium chloride injection, which were used to reconstitute vials of doxorubicin, were purchased from Bio Whittaker (Walkersville, MD) and Baxter Healthcare Corp. (Deerfield, IL), respectively. Animals and Animal Husbandry. One hundred sixty (80 male and 80 female) Sprague Dawley rats were obtained from Harlan Sprague Dawley (Madison, WI). All rats were approximately 7 wk of age at the inception of treatment. Certified Rodent Laboratory Chow #5002 (Purina Mills, St. Louis, MO) and fresh drinking water were provided ad libitum except for an overnight fast prior to scheduled blood sampling for clinicopathologic determinations and scheduled necropsies. Experimental Design. Six groups of 10 or 15 rats per sex were given single doses of either BMS-182248, doxorubicin, or DPBS intravenously into a tail vein at an injection rate of approximately 0.025 ml/sec. The intermediate and high doses of BMS-182248 contained sufficient amounts of doxorubicin that, if completely liberated, should have resulted in delayed cardiotoxicity in rats, because such toxicity has been reported in the literature from a 24mg/m2 dose of doxorubicin alone (14) . Necropsies were conducted on day 8, upon death/moribund sacrifice, or after an approximate 3-mo observation period following completion of treatment. The experimental design is summarized in Table 1 .
In-Life Observations and Measurements. The animals were observed daily for signs of toxicity and changes in general health and behavior while body weights were recorded prior to dosing and once weekly during the study. Blood samples for hematologic and/or serum chemistry determinations were collected via the caudal vein on day 4 and at approximately 2, 4, 7, 10, and 13 wk on test. Urine samples were collected prior to scheduled necropsies. Serum samples obtained predose and on study day 16 from rats were analyzed for the presence of anti-BMS-182248 antibodies. Anti-BMS-182248 antibodies were detected using an ELISA specific for BMS-182248. The assay consisted of coating 96-well ELISA plates with BMS-182248 (capture reagent), washing, adding serial dilutions (2 x ) of serum derived from test animals, washing, adding alkaline phosphatase-conjugated anti-rat IgG (detection reagent), washing, and adding para-nitrophenylphosphate (substrate) for color development. Absorbance was measured using an ELISA reader at 405 nm. The titer of a given sample was defined as the reciprocal of the last dilution that gave an absorbance reading greater than 2 times the predose absorbance reading for that animal. Pathological Examinations. Moribund rats and those at the scheduled day 8 and 3-mo necropsies were euthanatized with an intraperitoneal injection of sodium pentobarbital. Representative sections of the adrenal gland. bone. bone marrow. brain. cecum. colon, duodenum, epididymis. esophagus, eye, heart. ileum, injection site, jejunum. kidney. liver. lung, mammary gland, mandibular and mesenteric lymph node, ovary, pancreas, parathyroid, pituitary. prostrate, salivary gland, sciatic nerve, seminal vesicles, skeletal muscle, skin, spinal cord, spleen, stomach, testis, thymus, thyroid, tongue, trachea, urinary bladder, and uterus were collected from each rat of the appropriate sex and were fixed in 10% neutral-buffered formalin. Prior to fixation, the weights of the adrenals, brain, gonads, heart, kidneys, liver, pituitary, spleen, thymus, thyroid, and prostrate with seminal vesicles or uterus with cervix were recorded for each rat at scheduled necropsy.
Representative sections of organs and tissues were processed using conventional methods and were stained with H&E and periodic acid-Schiff stain (kidneys only).
Statistical Analysis. Comparison of clinical pathology and body weight data among treatment groups was made using an overall analysis of variance for variables with a parametric historical distribution. Pairwise comparison of treated groups versus controls were performed using Dunnett's multiple comparison procedure. For those variables with nonparametric historical distribution, groups were compared overall using the Kruskal-'~Vallis test followed by pairwise comparisons of treated groups to control using Steel's procedure.
RESULTS

Clinical Observations
No deaths occurred prior to the day 8 necropsy.
Three of 10 male and 1 of 10 female rats that received 2,550 mg/m2 BMS-1$2248 (74 mg/m2 doxorubicin equivalent) were sacrificed in moribund condition between days 29 and 92. Additionally, 1 high-dose female rat was sacrificed on day 74 for humane purposes because of a severe non-drug-related eye problem. In comparison, all 20 rats that received 72 ~nglm'-free doxorubicin died or were sacrificed in moribund condition between days 9 and 69. No deaths occurred in rats that received 1,200 mg/m2 BMS-182248 (34.8 mg/m'-doxorubicin equivalent) whereas 7 of 10 male and 2 of 10 female rats that received an equivalent dose of free doxorubicin died or were sacrificed in moribund condition between days 67 and 92. The mortality data is summarized in Table II. Drug-related clinical signs noted in rats that re- tension, whole-body paleness, ulceration of the tongue, tail lesions, thin body appearance, and teeth abnormalities. With the exception of ulceration of the tongue in BMS-182248-treated rats at a conjugated doxorubicin dose of 34.8 mglm2, these same clinical signs were observed in rats that received either 33.6 or 72 mg/mz free doxorubicin and were generally more pronounced and occurred with a higher frequency than in BMS-182248-treated rats. Swelling of the hindlegs and/or ventral posterior thorax, labored respiration, and tremors were additional observations noted exclusively in doxorubicin-treated rats. No drug-related clinical observations were noted in rats given BMS-182248 at a dose of 508 mg/m5.
Body 141'eight
At the end of the 3-mo dose-free observation period, slightly or moderately lower body weight gains were noted in rats that received 1,200 (mid-dose) or 2,500 (high dose) Mg/M2 BMS-182248 (169.8 and 119.8 g gain, respectively, vs 206.8 g gain for control males, 89.5 and 60.6 g gain, respectively, vs 93.1 g gain for control females). These differences were statistically significant for high-dose females. The average body weights of male and female rats that received BMS-18 2 248 at the low dose of 508 mg/ m2 were statistically comparable to respective control values. Surviving rats that received 33.6 mg/m2 doxorubicin displayed decreased body weight gains (females) or slight weight losses (males) at study termination that were more severe than those that occurred in comparably dosed BMS-18 ~ 248=treated rats. The 72-mg m2 doxorubicin group did not survive until study termination. The group body weight averages are presented in Fig. 1 . 
Clinical Pathology
Administration of BMS-182248 resulted in a minimal, generally dose-dependent decrease in white blood cells (WBCs), primarily lymphocytes (Table   III) . Administration of free doxorubicin resulted in a more severe decrease in WBCS, also affecting primarily lymphocytes. These early changes were generally reversible in BMS-182248-treated rats and low-dose doxorubicin-treated rats: but not in rats given the high dose of doxorubicin during the time they survived. By day 93, BMS-182248 interme-diate-dose males, high-dose males and females, and remaining free doxorubicin-treated females had slightly increased WBC counts compared to controls.
BMS-182248 (high-dose males only) and doxorubicin generally produced a minimal to mild anemia, respectively (Table III) . Red blood cell (RBC) parameters (hematocrit, hemoglobin, and RBC count) were decreased in doxorubicin-treated males and high-dose females from day 16 on, and in lowdose doxorubicin-treated females from day 51 on. Decreases in the same parameters were seen in B~1S-182248 high-dose males from day 29 on. and very minimal decreases were noted in intermediate-dose males and high-dose females from dav 72 on. Dosedependent decreases in reticulocytes were noted on day 4, most markedly for doxorubicin-treated rats (data not shown). Increased reticulocytes were generally. but not consistentlv. present in high-dose BMS-182248-treated rats and doxorubicin-treated rats after day 29.
A transient decrease in platelet count was observed during the first 2 wk of the study in all BMS-182248-treated male groups and in high-dose doxorubicin-treated females (data not shown). After the first 2 wk of the study, there was an absence of a consistent platelet effect for either BMS-182248 or free doxorubicin.
Drug-related serum chemistry changes consisted primarily of dose-related, often progressive, increases in cholesterol, triglycerides, globulins, blood urea nitrogen, creatinine, amylase, and lipase and decreases in albumin, alkaline phosphatase, aspartate aminotransferase, and albumin/globulin ratio (Tables IV and V). BMS-182248 intermediate-and highdose males and high-dose females had the majority of these changes at week 4, as did low-dose doxorubicin-treated males and females and surviving high-dose doxorubicin-treated females. In general, all values for BMS-182248-treated rats were less abnormal than the comparably dosed doxorubicintreated rats, with the possible exception of amylase. Alanine aminotransferase values were sporadically increased in doxorubicin-treated rats. Calcium, phosphorus, and electrolyte disturbances (data not shown) were also noted and were primarily limited to doxorubicin-treated rats and reflected the marked renal changes in these animals. Urinary protein increased in all males and treated female rats over the course of the study (data not shown).
Antibody Formation
As expected, none of the animals in the control group or in the groups treated with doxorubicin alone had a detectable titer of anti-BMS-182248 antibodies. Detectable titers of anti-BMS-182248 antibodies were demonstrated in 13 of 20 animals given 508 mg/m2 BMS-182248, in 12 of 20 animals given 1, 200 mg/m~ BMS-182248, and in 10 of 20 animals given 2,550 mglm'-BMS-182248. Titers ranged from 10 to 640. These results indicate that a single dose of BMS-182248 is capable of inducing the formation of antibodies against BMS-182248 in a majority of the rats treated. However. there appeared to be no clear differences, in either the frequency or magnitude of the anti-BMS-182248 antibody response, among any of the dose groups. c Values are the mean of surviving animals (n = 10 for the 3-mo necropsy except for Groups 4 and 6 (see Table It&horbar ;Mortality). * Significantly different from controls, p <_ 0.05.
Macroscopic Observations
At the early necropsy (day 8), there were BMS-182248-related decreases in the weights of thymuses, spleens, seminal vesicles, and testes (Table  VI) At the 3-mo necropsy, intermediate-dose BMS-182248 males had small testes (7 of 10) and 2 females had mammary tissue masses. Surviving, comparably dosed doxorubicin rats had pale kidneys, often with rough or granular cortical surfaces, small testes and seminal vesicles/prostates, small thymuses (males), and rare teeth abnormalities, and 1 female had a mammary tissue mass. Animals given 33.6 mg/m2 doxorubicin that died or were sacrificed in moribund condition generally had lesions similar to those found in surviving animals in this group at the scheduled necropsy. Lesions included small thymuses (males). pale kidneys, pancreatic edema (males), mineralized (stiff) aortas. and small testes and seminal vesicles prostates.
In the high-dose BMS-182248-treated rats, small thymuses, tongue ulcers, rare teeth abnormalities, pale or granular kidneys, and small testes and seminal vesicles/prostates were frequently observed. One female rat had a mammary tissue mass. All rats given a dose of free doxorubicin comparable to that in the high-dose group of BMS-182248 died prior to the scheduled necropsy. Males had frequent lesions of ascites, hydrothorax, and severe generalized edema (often involving pancreas, cecum, and perirenal tissue) as well as small thymuses, spleens, and seminal vesicleslprostates. Females lived slightly longer and, in general, had the same lesions as the males, plus pale kidneys.
Treatment with BMS-182248 was associated with increases in liver. spleen, and kidney weights for both males and females at the 3-mo necropsy (Table  VI) . Females given 33.6 mg'm2 free doxorubicin had increased liver. kidney, and ovary weights. Weights of testes and. to a lesser extent. seminal vesicles/ prostates, thymuses (males), and uteri were also decreased by either BMS-182248 (high dose) or doxorubicin administration. These changes were generally dose-related and more severe in doxorubicin-treated rats than comparably dosed BMS-! 82248-treated rats. No organ weights for high-dose doxorubicin-treated rats were obtained, as all animals had died by day 69.
Microscopic Observations
Significant histopathologic changes associated with BMS-182248 in the early phase of the study (day 8 necropsy) were typical of a cytotoxic agent (doxorubicin) and generally dose-related and involved urinary, reproductive, hematologic, and lymphoid tissues (Table VII ). In In the late phase of the study, lesions typical of doxorubicin cardiotoxicity were present in the highdose group of BMS-182248 (doxorubicin equivalent of 74 mg/m2) and were limited to 3 males and 1 female (Table VIII) . Three males had moderate vacuolation of cardiomyocytes and mild, moderate, or marked myocyte degeneration typical of doxorubicin toxicity. The single female had minimal vacuolation of cardiomyocytes suggestive of doxorubicin toxicity (Fig. 2) . In contrast, rats given a comparable dose of free doxorubicin (72 Mg/M2), particularly females, had much more severe vacuolation and degeneration of myocytes in both atria and ventricles. Early changes consisted of vacuolation of myocytes, followed by displacement and loss of myofibrils, fibrosis, and atrophy ( Fig. 3 ). Because of the time required for this lesion of delayed cardiotoxicity to develop, high-dose doxorubicintreated males, which died or became moribund earlier, had less severe lesions than either the high-dose females or the low-dose doxorubicin-treated rats.
No high-dose doxorubicin-treated males survived beyond day 25. Changes of a delayed nature and requiring time to fully develop were most severe and were present in all 20 rats given 33.6 Mg/M2 free doxorubicin, with males having slightly more severe lesions than females. Rats given the intermediate dose of BMS-182248, containing a comparable dose of doxorubicin (34.8 Mg/M2), had no drug-related cardiac lesions. Lesions consistent with spontaneous cardiomyopathy (inflammation, single-cell necrosis, or degeneration) were seen in all groups but were minimal and clearly differentiated from doxorubicin-induced toxicity. Myocardial TABLE VIII.-Incidence of selected drug-related histopathologic findings in heart and kidney of rats given BMS-182248 or doxorubicin (3-mo necropsy).
Abbreviations: F = female; M = male. &dquo; Ten rats per sex per group. & d q u o ; Three of 10 males and I female were killed moribund between days 29 and 92, and I female was sacrificed for humane reasons on day 74. , All rats died or were sacrificed moribund between days 9 and 69. ' Seven males and 2 females died or were sacrificed moribund between days 67 and 92. mineralization was most prevalent in low-dose doxorubicin-treated rats, reflecting the severe renal changes in that group (data not shown).
BMS-182248 administration produced a dose-dependent glomerulonephropathy (degeneration and regeneration of tubular epithelium, tubular dilation, casts, thickened basement epithelium, and inflammatory cells, primarily mononuclear cells), glomerulosclerosis, and glomerular vacuolation (Table  VIII) . These effects were minimal in the low-dose group but became more pronounced in the intermediateand high-dose groups (Fig. 4 ). Males were more severely affected than females. In comparison, doxorubicin-treated rats had more severe renal lesions at comparable doses (Fig. 5 ) as well as the more severe clinical pathologic changes of nephrotoxicity mentioned previously. Bone marrow changes noted at the day 8 necropsy had largely regressed by end of the study. Minimal to mild bone marrow hypocellularity was present at the 3-mo necropsy in I male given the intermediate dose of BMS-182248 and 6 males given the high dose of BMS-182248. In contrast, rats given free doxorubicin, comparable to that present in the intermediate and high doses of BMS-182248. had more severe changes (Table IX) . The IX.-Incidence of selected drug-related findings in nervous, hematopoietic, lymphoid, and reproductive tissues of rats given BMS-182248 or doxorubicin (3-mo necropsy).
Abbreviations: F = female; M = male. &dquo; Ten rats per sex per group. &dquo; Three of 10 males and I female were sacrificed moribund between days 29 and 92 and I female was sacrificed for humane reasons on day 74. , All rats died or were sacrificed moribund between days 9 and 69. ' Seven males and 2 females died or were sacrificed moribund between days 67 and 92. viving females in the low-dose doxorubicin group had minimal hypocellularity, and 1 was within normal limits, whereas the 2 killed moribund had minimal and mild hypocellularity. In comparison, all 10 BMS-182248-treated females given a comparable dose of doxorubicin were within normal limits. Similarly, rats treated with the high dose of free doxorubicin (72 Mg/M2) had minimal to moderate hypocellularity.
Rats that survived to the 3-mo necropsy, either doxorubicinor BMS-182248-treated, had essentially normal spleens, indicating reversibility of BMS-182248 or doxorubicin treatment-related effects (Table IX) . Several high-dose and 1 intermediate-dose BMS-182248-treated females had increased extramedullary hematopoiesis compared to controls (data not shown). Depletion of splenic red pulp and lymphoid tissues was seen in 2 high-dose BMS-182248-treated males. One was killed moribund on day 29 and the other was sacrificed on day 72 with severe cardiac and renal lesions. Doxorubicin-treated rats that died or were sacrificed in mor-ibund condition, both high and low dose, had more severe depletion of red pulp and lymphoid elements than BMS-182248-treated rats.
The majority of BMS-182248-treated rats had normal thymuses at the 3-mo necropsy (Table IX) . Minimal thymic atrophy was present in 1 BMS-182248 intermediate-dose male, and mild atrophy was present in 1 high-dose male and female at the 3-mo necropsy. Rats killed moribund or that died early had minimal and moderate (females) or moderate to marked (males) thymic atrophy. Similar results were seen in free doxorubicin-treated rats. Females given a doxorubicin dose comparable to the intermediate dose of BMS-182248; and that survived to the 3-mo necropsy; had normal thymuses. Virtually all males given free doxorubicin had moderate to marked thymic atrophy, whereas 8 of 10 females given the high dose of doxorubicin had mild to marked atrophy. Most of these rats died early in the study. Testicular (Table IX) . Testicular atrophy was generally dose-related, primarily mild to moderate in lowdose rats and marked in intermediateand highdose rats. Two rats given the high dose of BMS-182248 were unusual, because little or no effect on testes was observed in these rats. These 2 rats also had other organs that were generally unaffected compared to the rest of their dose group.
Doxorubicin treatment resulted in similar, though less severe, lesions in testes. However, this may be somewhat misleading due to the poor survivability of doxorubicin-treated males. Acute lesions of degeneration were present in males given the high dose of doxorubicin, all of which had died or were killed moribund by day 25. Three males given 33.6 mg/ m2 free doxorubicin did survive to the 3-mo necropsy, compared to all 10 of the BMS-182248-treated males given the same doxorubicin equivalent. Testes in the 3 free doxorubicin survivors appeared to have some islands of spermatogenesis that were not seen in BMS-182248-treated rats. This suggests some recovery in the free doxorubicin-treated but not BMS-182248-treated rats.
Rats given BMS-182?48 and necropsied at 3 mo had a dose-related degeneration of axons in the sciatic nerve. the dorsal funiculus of the spinal cord. and the trigeminal nerve tract of the medulla ob-longata ( Fig. 6 ). Rats given 33.6 mg/m~ doxorubicin had a similar incidence and severity of axonal changes compared to rats given BMS-182248 with a comparable dose of doxorubicin (Table IX) . Rats given the high dose (72 mg/m2) of doxorubicin did not survive to the 3-mo necropsy and, consequently, had less severe lesions than comparable BMS-182248-treated rats (Fig. 7 ) since a period of time is required for these lesions to develop.
Administration of doxorubicin or BMS-182248 was associated with changes in other tissues (data not shown), including altered, hypereosinophilic gastric chief cells, increased hepatic extramedullary hematopoiesis, teeth abnormalities, adrenal gland vacuolation, vacuolation of corpora luteal cells, uterine atrophy, seminal vesicle atrophy, ulceration and myofiber degeneration/regeneration of the tongue, increased osteoclastic and osteoblastic activity in bone, and mandibular lymph node hyperplasia. Additionally, doxorubicin treatment was associated with several findings generally not present in BMS-182248-treated rats, including salivary gland degeneration: edema in lymph nodes, gastrointestinal tissues. and lungs: mineralization and degeneration in various tissues such as stomach, lung, kidney, and mesenteric vessels: vacuolation and degeneration of atrial mv ohbe rs along pulmonary 
DISCUSSION
The major toxicities observed in the rat following administration of BMS-182248 or doxorubicin were (a) delayed cardiotoxicity, (b) glomerulonephropathy, (c) radiomimetic-type toxicity to tissues with active cell replication (bone marrow, lymphoid tissue, and testes), and (d) neuropathy, as noted by axonal degeneration and related changes. These toxicities were all considered to be related to doxorubicin and have been previously reported for doxorubicin and other anthracyclines (1, 2, 5, 10). A significant reduction in delayed cardiotoxicity was demonstrated in rats given a single dose of doxorubicin conjugated to BR96 monoclonal antibody (BMS-182248) compared to that observed in rats given an equivalent dose of free (unconjugated) doxorubicin. The cardiotoxicity observed in 4 of 20 rats given a single dose of 2,550 mg/m2 BMS-182248 (74 Mg/M2 doxorubicin equivalent dose) suggests that some level of free doxorubicin (either released from the BR96 antibody or unbound) was present in the circulation and myocardium or that some minimal amount of BMS-182248 was taken up by myocardium with subsequent intracellular release of doxorubicin. The latter is less likelv, because rat myocardium has little Lewis' antigen expression (unpublished data). In addition, the cardiac lesions indicate that sufficient time was allowed for manifestation of delayed effects. The highest dose of BMS-182248 that has been shown to be noncardiotoxic in rats was demonstrated in multiple-dose studies conducted in our laboratories. Using a cardiotoxic regimen reported for free doxorubicin by Lanza et al (8) , in which they administered 3 doses of 18 mg/ m 2, 1 dose every third day, no cardiotoxicity occurred with BMS-182248 at a cumulative doxorubicin equivalent dose of 57.9 mg/m2. In contrast, the cardiotoxicity observed in rats in the present study given a single dose of 33.6 mg/m2 free doxorubicin is consistent with that of Yeung et al (14) , who reported cardiotoxicity in rats given a single 24-Mg/M2 dose of doxorubicin.
Experimentally, doxorubicin produces a marked proteinuria in rats within 4-5 days of intravenous infusion and induces a significant glomerulonephropathy with characteristic lesions in rats (1) . Renal changes are characterized by the presence of vacuoles in glomerular epithelial cells and focal or segmental glomerular sclerosis as well as concurrent tubular damage and regeneration (casts, protein resorption droplets, and tubular basophilia). Proteinuria or nephrotic syndrome (proteinuria, decreased serum albumin, and increased cholesterol) eventually develops (1) . Increased blood urea nitrogen and creatinine probably reflect the increasingly compro-mised renal function in both BMS-182248and doxorubicin-treated rats, with uremia developing in many rats. The increased amylase and lipase may reflect impaired renal function, as no consistent morphological changes were seen in the pancreas or salivary gland to explain the increases in these 2 enzymes.
Aspartate aminotransferase and alkaline phosphatase were, in general, minimally decreased in male and female rats by treatment with either doxorubicin or BMS-182248. These changes probably represent effects on muscle and bone, respectively, and most likely reflect decreased growth rate compared to controls. Bone changes have been reported following doxorubicin administration, which may also be reflected in the decreased alkaline phosphatase levels (5) . Although alanine aminotransferase activity was minimally increased, the only liver change noted was an increase in liver weight, which has been associated with doxorubicin administration in rats (7) , as was noted here.
The results of the examination of bone marrow, spleen, and thymus suggest that the effects of BMS-182248 on hematopoietic and lymphoid tissues are generally reversible and less severe than doxorubicin, a finding also reflected in the clinical pathology data. Doxorubicin does not cross the blood-brain barrier but has been reported to cause a neuronopathy in rats at 5 and 10 mg/kg (30 and 60 Mg/M2). This neuronopathy primarily involves peripheral ganglia, including spinal, paravertebral, and trigeminal ganglia, which are outside the blood-brain barrier. One result of this toxicity is the presence of axonal degeneration in related peripheral nerves or nerve tracts. Although the neuronal changes occur fairly early, the axonal degeneration takes more time to develop, which may explain the slightly more severe lesions in high-dose BMS-182248-treated rats than doxorubicin-treated rats, all of which died prior to the end of the study. Higher doses of doxorubicin reportedly produce the neuronopathy (and likely associated axonal degeneration) at slightly earlier time points (2, 6) . The possible clinical importance of these lesions is problematic, as neurotoxicity is not considered a doxorubicin toxicity of concern in human use (9, 12) . The lack ofa consistent, strong, antibody response against BMS-182248 is somewhat surprising. Immunologically, BMS-182248 is a &dquo;haptenated&dquo;-human IgG (Dox-IgG,) and therefore should appear foreign to the rat immune system. These data suggest that, because the antigen (i.e.. BMS-182248) is cytotoxic, antigen-specific B cells may be killed. thereby limiting an antigen-specific antibody response. Alternatively, the doses of BMS-182248 employed in this study may be supraoptimal and may be capable of inducing antigen-specific tolerance (i.e.. antigen-specific nonresponsiyeness).
In summary, the qualitatiwe toxicologic profile of BMS-182248 in rats is similar to doxorubicin. and all toxicities are considered to be due to doxorubicin. However, when compared at equivalent doses of doxorubicin. BMS-182248 is significantlv less toxic, and this is particularly true with respect to cardiotoxicity.
